ComplyRx
Built by ComplyRx

Compare clinical trial pipelines, export for presentations

dupilumab (16) vs risankizumab (16)15 active2013–2033
dupilumabrisankizumab
Key
Actual date
Anticipated
Forecast to primary completion
RecruitingActive, not recruitingNot yet recruitingCompleted
'13
'15
'17
'19
'21
'23
'25
'27
'29
'31
'33
dupilumab
Open-label Study of Dupilumab in Patients With Atopic DermatitisP3
Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)P3
VENTUREP3
A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically AdvisableP3
VOYAGEP3
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)P3
Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)P2
IDEAP4
Level UpP3
TORNADOP4
AIM4:Next StepP4
WIDUSAP4
A Phase Ⅲ Comparative Study of QL2108 to Dupixent®P3
Tapering of Biologics in Chronic Rhinosinusitis With Nasal PolypsP4
HOTHOTP3
A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic DermatitisP2
risankizumab
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisP3
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatmentP3
BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisP3
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative ColitisP2
FORTIFYP3
Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque PsoriasisP3
KEEPsAKE2P3
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or IxekizumabP3
SOPRANO-CDP4
PATHFINDERP4
AFFIRMP3
IMMpactfulP4
Target CDP2
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic ArthritisP3
CHARGEP3
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative ColitisP2

Upcoming readouts

14 ahead · 2 drugs

Select a trial to load its full ClinicalTrials.gov record.

Trial Pipeline · How it works

Search, compare, export.

Three steps from drug name to a presentation-ready pipeline view, with live trial data, side by side.

  1. 01 · SEARCH

    Search drugs

    Type a drug name and see the phase 2-4 trials from ClinicalTrials.gov.

  2. 02 · COMPARE

    Compare timelines

    See start dates, primary completions, and status on one timeline, up to five drugs at once.

  3. 03 · EXPORT

    Export for your deck

    Download a branded PNG or PDF. Share the URL. Every comparison state is linkable.

FAQ

Where does the data come from?
All trial data is sourced from ClinicalTrials.gov (CTGov). Results are cached for up to 6 hours so repeat loads stay fast.
Is this free?
Yes. Compare up to five drugs and export PNG or PDF at no cost. Export requires a one-time email to join the ComplyRx waitlist.
What is ComplyRx?
ComplyRx is an all-in-one marketing/competitive intelligence platform for organisations and individuals that work in healthcare, life sciences, and the pharmaceutical industry.
Join the waitlist

Be the first to access ComplyRx

We'll let you know as soon as your spot opens to use ComplyRx.

By joining, you agree to our Privacy Policy.